検索結果

Management Policy | About Senju | SENJU Pharmaceutical

“Being a good company” is our management policy. As a company that aims to be reliable, necessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju

General Announcement: July 8, 2024 Senju Pharmaceutical Co., Ltd. Notice of Orphan Drug Designation for SJP-0008 as a Treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Head

Data And Statistics | About Senju | SENJU Pharmaceutical

Sales Revenue. Operating Profit and Ordinary Profit 2020.3 2021.3 2022.3* 2023.3* 2024.3* Sales Revenue 41.2 40.7 40.8 46.4 48.9 Operating Profit 2.2 5.4 6.9 7.4 7.1 Ordinary Profit 4.3 8.0 9.1 8.7 9.

General Announcement: May 9, 2024 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion S

Research Laboratories | About Senju | SENJU Pharmaceutical

Distinguished by technological leadership, our exclusive research system enables us to investigate the infinite possibilities that science holds for humanity At senju Pharmaceutical, we take an open-m